RxDoctor Payments Data

Irene Oh, MD

Neurology · Carlsbad, CANPI 1306089008

Payments from drug & device makers

$15,808in general payments, 2019–2025

Across 842 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$1K
  • Sunovion Pharmaceuticals Inc.$1K
  • SK Life Science, Inc.$874
  • Lundbeck LLC$635
  • Medtronic$610
  • plus $8K from 51 others

What the payments were for

  • Speaking & faculty fees$1301%
  • Food & beverage$15,61699%
  • Education$20%
  • Gifts$600%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)158$3,381
UCB, Inc.78$1,451
Sunovion Pharmaceuticals Inc.93$1,341
SK Life Science, Inc.65$874
Lundbeck LLC39$635
Medtronic(3 entities)11$610
Neurocrine Biosciences, Inc.29$566
Boston Scientific12$554
Teva Pharmaceuticals USA, Inc.35$537
Abbott18$468
Novartis25$365
Acadia Pharmaceuticals Inc23$351
Amgen(2 entities)18$333
MDD US Operations, LLC15$320
GE HealthCare9$295
Amneal Pharmaceuticals LLC19$288
Adamas Pharmaceuticals, Inc.17$277
Lilly USA, LLC20$259
Biogen16$247
Neurelis, Inc.18$241
Jazz Pharmaceuticals Inc.10$213
Pfizer11$195
Kyowa Kirin, Inc.9$173
Saol Therapeutics Inc.5$163
Livanova USA, Inc.7$154
Acorda Therapeutics, Inc6$130
Merz North America, Inc.6$125
Eisai Inc.6$121
Arbor Pharmaceuticals, Inc.7$99
Impel Pharmaceuticals LLC5$93
Avanir Pharmaceuticals, Inc.4$70
Vertical Pharmaceuticals, LLC3$66
Impel Pharmaceuticals Inc.3$61
Scilex Pharmaceuticals Inc.4$60
Averitas Pharma Inc.2$56
Insightec,inc3$53
CSL Behring3$49
Johnson & Johnson(2 entities)2$47
Merz Pharmaceuticals, LLC2$46
Alnylam Pharmaceuticals Inc.2$46
Aquestive Therapeutics, Inc.2$43
Catalyst Pharmaceuticals, Inc.2$37
Upsher-smith Laboratories LLC2$36
Tanabe Pharma America, Inc.2$34
Supernus Pharmaceuticals, Inc.2$30
Avadel CNS Pharmaceuticals, LLC1$25
Nevro Corp.1$24
Corium, LLC1$24
Greenwich Biosciences, Inc.1$20
Grifols USA, LLC1$20
W. L. Gore & Associates, Inc.1$19
Biohaven Pharmaceutical Holding Company Ltd.1$18
Axsome Therapeutics, Inc.1$18
Otsuka America Pharmaceutical, Inc.1$17
Assertio Therapeutics, Inc.1$14
Biohaven Pharmaceuticals, Inc.1$14
Travere Therapeutics, Inc.3$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,808 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$993,687
Medicare patients
804
Services billed
94,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate137$775,724
RytaryCarbidopa/Levodopa631$627,726
SkyclarysOmaveloxolone11$354,312
GocovriAmantadine Hcl55$238,781
NeuproRotigotine87$117,830
Rasagiline Mesylate402$87,155
DuopaCarbidopa/Levodopa12$71,057
XadagoSafinamide Mesylate33$68,396
BotoxOnabotulinumtoxina36$37,636
Carbidopa-LevodopaCarbidopa/Levodopa897$31,147
XeominIncobotulinumtoxina14$20,154
Rivastigmine54$16,490
Entacapone47$13,263
Pramipexole ErPramipexole Di-Hcl24$13,138
Tetrabenazine28$11,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$351$775,724137 claims
Amneal Pharmaceuticals LLCRytary$288$627,726631 claims
BiogenSkyclarys$247$354,31211 claims
MDD US Operations, LLCGocovri$320$238,78155 claims
UCB, Inc.Neupro$1,451$117,83087 claims
AbbVieDuopa, Botox$3,381$108,69348 claims
Merz North America, Inc.Xeomin$125$20,15414 claims
Upsher-smith Laboratories LLCTopiramate$36$1,06085 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →